Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis
Nan Ma, … , Weiqin Li, Jieshou Li
Nan Ma, … , Weiqin Li, Jieshou Li
Published September 27, 2022
Citation Information: JCI Insight. 2022;7(21):e161244. https://doi.org/10.1172/jci.insight.161244.
View: Text | PDF
Research Article Gastroenterology Inflammation

Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis

  • Text
  • PDF
Abstract

Acute pancreatitis (AP) is a local and/or systemic inflammatory disease that starts with acinar cell injury and necrosis; it has no effective medical treatment and thus remains a life-threatening condition. Interleukin-37 (IL-37), a natural immunomodulator, has demonstrated an antiinflammatory effect; however, the role of IL-37 in AP remains unknown. The serum IL-37 levels of 39 healthy controls and 94 patients with AP were measured. Cholecystokinin was applied to induce pancreatic acinar cell injury in vitro. Classical experimental AP models, such as caerulein, l-arginine, and taurolithocholic acid 3-sulfate disodium salt, were included in the in vivo study. A transgenic mouse model with the IL-37 gene and administration of recombinant IL-37 were used to further investigate the function of IL-37 in AP. Pancreas-specific gasdermin D–knockout (GSDMD-knockout) mice were used to explore the protective mechanism of IL-37. Our results showed that serum IL-37 levels in humans were negatively correlated with the severity of AP. Furthermore, IL-37–transgenic mice and supplementation with recombinant IL-37 could both protect against AP. Mechanistically, IL-37 was able to suppress pyroptosis of injured acinar cells, and specific depletion of GSDMD in the pancreas counteracted the protective effect of IL-37. Our study demonstrates that IL-37 protects against acinar cell pyroptosis in AP.

Authors

Nan Ma, Chenchen Yuan, Juanjuan Shi, Qingtian Zhu, Yang Liu, Xiaojie Ma, Baiqiang Li, Weijuan Gong, Jing Xue, Guotao Lu, Weiqin Li, Jieshou Li

×

Figure 5

IL-37 suppresses GSDMD-mediated pyroptosis of acinar cells in AP.

Options: View larger image (or click on image) Download as PowerPoint
IL-37 suppresses GSDMD-mediated pyroptosis of acinar cells in AP.
(A) 26...
(A) 266-6 cells were stimulated with CCK and treated or not treated with rIL37 (10 or 50 ng/mL) for 12 hours. Caspase-1 and PI staining was performed to identify pyroptotic cells. Representative flow cytometry gating and proportion of double-positive cells are shown. (B and C) Pancreatic tissues collected from mice were stained with anti-GSDMD and anti-NLRP3 antibodies. (B) Representative images and quantitative analysis for GSDMD and NLRP3 staining of pancreatic tissues from IL37tg and WT mice with or without CAE-AP (n = 3 per group). (C) Representative images and quantitative analysis for cleaved GSDMD and NLRP3 staining in pancreatic tissues of the AP group and the rIL37-treated group (5 μg/kg) (n = 3 per group). Scale bars: 50 μm. (D and E) Western blot analyses and quantification of the expression of GSDMD (pro- and cleaved), NLRP3, and caspase-1 (pro- and cleaved) in pancreatic tissues from the indicated mice (n = 3 per group). Experiments were repeated 3 times. Statistical comparisons were made using 1-way ANOVA. Data are presented as mean ± SD, and statistical significance is denoted as *P < 0.05, **P < 0.01, and ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts